Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies

AbstractPurpose of ReviewThis review aims to summarize evidence regarding hepatocellular carcinoma (HCC) screening in the specific context of HIV infection and discuss areas of uncertainty.Recent FindingsIt has not been definitely established if HCC incidence in HIV/HCV-coinfected patients with cirrhosis is above the 1.5%/year threshold that makes screening cost-effective. Outside cirrhosis or HBV infection, available data do not support surveillance. The performance of currently recommended ultrasound (US) screening strategy is poor in HIV-infected patients, as rates of early-stage HCC detection are low. Magnetic resonance imaging –based surveillance strategies or liquid biopsy are innovative approaches that should be specifically tested in this setting.SummaryHIV-infected patients with cirrhosis are at risk of HCC. US surveillance identifies patients with early-stage HCC who will benefit of curative therapies, although the quality of the evidence supporting screening remains limited. The HIV population should be a priority group to assess and validate new surveillance strategies.
Source: Current HIV/AIDS Reports - Category: Infectious Diseases Source Type: research